Effectiveness of Cordyceps sp. and Beauveria Bassiana Against Large Cabbage-heart Caterpillar, Crocidolomia Pavonana Fabricius (Lepidoptera: Crambidae)

Crocidolomia pavonana Fabr. (Lepidoptera: Crambidae) is a major pest on various cabbage crops in Indonesia. Various insecticides have been used to control this insect pest including several entomopathogenic fungi, and this cabbage caterpillar has become resistant to various insecticides. In order to develop insecticides from entomopathogenic fungi, species or varieties from natural area such as forest are needed. A bioassays of Cordyceps sp. and Beauveria bassiana has been carried out in the laboratory. Inoculum of Cordyceps sp. obtained from the Dipterocarpaceae forest in South Kalimantan, Indonesia recovered from dead ants by the mycelium of Cordyceps sp. Four concentration of Cordyceps sp. and Beauveria bassiana inoculum and tween80 as a control were tested against 3rd instar larvae of C. pavonana with five replications. Field efficacy trial was carried out in a screen house (8 x 12 M2) using Chinese cabbage plants (Brassica juncea) aged 28 days after sowing, with a spacing of 0.4 M between rows. Three formulation of Cordyceps sp. and tween80 as a control were used with 6 replications. The result of the bioassays in the laboratory showed that Cordyceps sp. with concentration of 1 x 107 conidia mL-1 was able to give 100% mortality od C. pavonana larvae, while B. bassiana with the same concentration caused morality of C. pavonana larvae of 98.33%, although statistically not significantly different. The results of probit analysis also showed that LC90 Cordyceps sp. against cabbage caterpillar larvae was 1.57 x 106 conidia mL-1, while B. bassiana required a concentration of 2.6 x 106 conidia mL-1 to reach the LC90 value. The results of filed trial showed that the formulation of Cordyceps sp. 1 x 107 conidia mL-1 using palm oil cooking oil was able to give an average mortality of 86.7%, and significantly higher (P<0.05) than the other treatment. The results of this study indicate that the inoculum of Cordyceps sp. from Dipterocarpaceae forest is very promising to be developed as an insecticide to control C. pavonana in cabbage

Indicated, Internet-based Prevention for Women With Anorexia Nervosa Symptoms: A Randomised Controlled Efficacy Trial (Preprint)

BACKGROUND While preventive interventions for eating disorders in general have shown promise, interventions specifically targeting individuals at risk for anorexia nervosa have not been evaluated. OBJECTIVE To determine the efficacy of a guided, indicated, Internet-based prevention program for women at risk for anorexia nervosa (AN). METHODS Randomized, controlled efficacy trial for women at risk for AN. Assessments at baseline (pre), post-intervention (10 weeks after baseline), 6-, and 12-month follow-up (FU). 168 women with low body weight (17.5≤BMI≤19) and high weight concerns, or with normal body weight 19<BMI≤25, high weight concerns and high restrained eating were recruited from three German universities as well as online, and randomized to Student Bodies-AN (SB-AN) or a waiting list control group (CG). Exclusion criteria were current DSM-IV full-syndrome AN, bulimia nervosa or binge eating disorder, serious medical or mental problems, such as current substance abuse, acute or chronic organic or schizophrenic psychosis, severe suicidal ideation or behaviour, no Internet access. Interventions: 1. Cognitive-behavioural, guided, Internet-based prevention program (SB-AN) over 10 weeks (IG); 2. Waiting list control condition (CG). Primary outcomes were clinically significant changes in attitudes and behaviours of disordered eating, and change in BMI in the underweight group of participants at 12-month follow-up. Secondary outcomes are new onset of eating disorders, symptoms of disordered eating, and associated psychopathology. RESULTS Data were available at post-intervention for N=137 women, and for N=116 women at 12-month FU. At 12-month FU, IGs participants showed larger decreases in EDE Total scores (79% vs. 57%) compared to the CG, and underweight IG participants also showed larger clinically relevant increases in BMI (49% vs. 32%) compared with underweight CG participants, but these differences were not significant. In addition, at post-intervention and 12-month follow-up, we found a significant increase in continuously measured BMI for underweight participants and significant improvements in attitudes and behaviours of disordered eating (e.g., restrained eating, weight and shape concerns). At all time points, rates of newly emerging ED onset cases were (non-significantly) lower in the IG compared with the CG and reductions in DSM-5-based ED syndromes were (non-significantly) higher in the IG compared with the CG. CONCLUSIONS SB-AN is the first preventive intervention shown to significantly reduce specific risk factors and symptoms for AN and shows promise for reducing full-syndrome AN onset. CLINICALTRIAL ISRCTN70380261

Efficacy and safety comparison between 1927 nm thulium laser and 2940 nm Er:YAG laser in the treatment of facial atrophic acne scarring: a prospective, simultaneous spilt-face clinical trial

Acne scarring is a common disfiguring complication of acne, and fractional lasers are widely applied in improving it. This study is to compare the efficacy and safety of fractional non-ablative 1927 nm thulium laser (FTL) and fractional ablative 2940 nm Er:YAG laser (FEL) in the treatment of acne scarring. Subjects with moderate or severe atrophic facial acne scarring received 3 sessions of FTL on the left side of face and FEL on the right side of face at an average interval of 4–6 weeks. Major assessments included Goodman&Baron quantitative global scarring grading system (GBS), self-rated improvement and satisfaction score. Twenty-seven subjects completed the study; for FTL side, average GBS decreased from 11.15 ± 5.04 at baseline to 7.07 ± 4.87 with an improvement percent of 36.54%; for FEL side, average GBS decreased from 10.81 ± 4.46 to 7.00 ± 4.07 with an improvement percent of 35.27%. Adverse effects include transient pain, erythema, edema, and increase of acne. No significant difference was found between two lasers. Both FTL and FEL improved atrophic acne scarring and were well-tolerated. Increase of acne during laser treatment may have a negative impact on efficacy. Trial registration number was NCT04813419 and date of registration was 19th, March, 2021, retrospectively registered.

The movement-to-music (M2M) study: study protocol for a randomized controlled efficacy trial examining a rhythmic teleexercise intervention for people with physical disabilities

Background People with physical disabilities need exercise routines that are enjoyable, readily available in the home, adapted to their functional level, and eliminate common barriers to exercise participation related to transportation and time commitment. The purpose of the movement-to-music (M2M) study is to address these issues by establishing a remotely delivered, rhythmic exercise program for people with physical disabilities. Methods The study is a two-arm randomized controlled efficacy trial examining a 12-week remotely delivered M2M intervention (eM2M) in 108 people with physical disabilities. The primary outcomes are changes in cardiorespiratory fitness and muscle strength at post 12-week intervention. Discussion The eM2M study will enhance our understanding of an alternative intervention design and delivery mode that removes common barriers to exercise participation experienced by people with physical disabilities. The eM2M intervention may be an alternative option for people with physical disabilities to obtain regular exercise, especially during a pandemic when exercising in indoor facilities may be problematic. Trial registration ClinicalTrials.gov NCT03797378. Registered on January 9, 2019, with the trial name “Movement-to-Music: Lakeshore Examination of Activity, Disability, and Exercise Response Study (M2M LEADERS)”.

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines.